All In Biotech

Drug Trial Radar · NCT01421511

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of IV to Oral 6-Day TR-701 Free Acid and IV to Oral 10-Day Linezolid for the Treatment of ABSSSI

Last checked: Nov 20, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 666 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

666

Actual

Start

Sep 15, 2011

Primary completion

Jan 10, 2013

Study completion Jan 10, 2013

Sponsor

Sponsor type
Industry
First posted
Aug 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to oral TR-701 FA 200 mg once daily for 6 days versus IV to oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults. Patients are to start treatment with at least 2 IV doses and may receive IV therapy for the entire treatment duration. Approximately 100 to 140 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment.

Conditions

  • Skin and Subcutaneous Tissue Bacterial Infections

Interventions

  • TR-701 FADrug

    * TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion * TR-701 FA Tablets, 200 mg, orally once daily

  • LinezolidDrug

    * Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion * Linezolid Tablets, 600 mg, orally every 12 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Early Clinical Response RateTime frame: 48-72 hours

Locations

117 sites in 11 countries. Site status is shown where the registry gives one.

  • Trius investigator site 159

    Dothan, Alabama

  • Trius investigator site 103

    Chula Vista, California

  • Trius investigator site 143

    Escondido, California

  • Trius investigator site 105

    La Mesa, California

  • Trius investigator site 106

    Long Beach, California

  • Trius investigator site 157

    Long Beach, California

  • Trius investigator site 142

    National City, California

  • Trius investigator site 170

    San Diego, California

  • Trius investigator site 167

    Santa Ana, California

  • Trius investigator site 168

    Stockton, California

  • Trius investigator site 141

    Sylmar, California

  • Trius investigator site 139

    Denver, Colorado

  • Trius investigator site 137

    Newark, Delaware

  • Trius investigator site 166

    Edgewater, Florida

  • Trius investigator site 101

    Columbus, Georgia

  • Trius investigator site 138

    Carmel, Indiana

  • Trius investigator site 144

    Owensboro, Kentucky

  • Trius investigator site 150

    Baton Rouge, Louisiana

  • Trius investigator site 165

    Eunice, Louisiana

  • Trius investigator site 154

    Boston, Massachusetts

  • Trius investigator site 146

    Springfield, Massachusetts

  • Trius investigator site 136

    West Roxbury, Massachusetts

  • Trius investigator site 163

    Royal Oak, Michigan

  • Trius investigator site 153

    Minneapolis, Minnesota

  • Trius investigator site 149

    Picayune, Mississippi

  • Trius investigator site 164

    Creve Coeur, Missouri

  • Trius investigator site 160

    Las Vegas, Nevada

  • Trius investigator site 147

    Teaneck, New Jersey

  • Trius investigator site 140

    Columbus, Ohio

  • Trius investigator site 162

    Lima, Ohio

  • Trius investigator site 161

    Rapid City, South Dakota

  • Trius investigator site 155

    Franklin, Tennessee

  • Trius investigator site 145

    Memphis, Tennessee

  • Trius investigator site 169

    Smyrna, Tennessee

  • Trius investigator site 148

    Houston, Texas

  • Trius investigator site 354

    Buenos Aires, Argentina

  • Trius investigator site 355

    Buenos Aires, Argentina

  • Trius investigator site 351

    Cludad Autonoma de Buenos Aires, Argentina

  • Trius investigator site 358

    La Plata, Argentina

  • Trius investigator site 357

    Mar del Plata, Argentina

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.